You may also enter through Nippon India Japan equity fund.

I was just checking their banking app Unity SFB on Play Store. It has only two star rating and very bad reviews by the users. Being completely digital bank they should have a very good app. Any user experience here in this forum?

This is the old one or a completely new one?

Thank you @mantis1 for such an amazing write up about the company. It saved me time in making my own notes about it. To add to your write up, I have done my own analysis about the company as I’ve recently taken an exposure in it. The below highlights my rationale behind investing in the company,

Growth:

• Company owned clinics are going to expand from ~400 in FY24 to ~1000 in the next 3-5 years.

• Current hospitals in Khopoli and Nagpur are going to see their beds double in the next 12 months. Eventually, 8 more hospitals/health resorts are going to be launched in the next 3-5 years.

• A lot of the infrastructure, personnel and marketing costs are being incurred upfront. As sales kick in and these margins stabilize and become efficient over time, the business will see a good margin kicker coming in. Furthermore, the company’s plan on backward integration for its food kits will improve the margins further. All of this will flow to the bottom line. Thus, there is a nice operating leverage play waiting to happen here.

• Growth in the patients visiting these clinics and hospitals as the brand and the treatment it offers becomes more visible. This will happen through word of mouth (more patients = more gospel being spread), marketing spends, tailwinds in the sector with the government pushing ayurveda through the ministry of Ayush (just like it pushed Yoga).

• Launch of its B2C products in offline stores and setting up offline distribution for the same.

Company/industry potential:

• Unorganised to organised theme at play here for ayurveda treatment.

• The company is adding value by offering a chance for disease reversal using ayurveda viz a viz allopathy and doing so at a lower costs. This is the value migration at play here.

Risks:

• EXECUTION. The single BIGGEST risk. The company and its promoter have set really high goals for themselves. They may not be able to achieve this in the timeframe they’ve set or the quality of services and products may suffer as they scale. They may not be able to scale margins beyond excel projections. People may remain skeptical of ayurveda and the patients will not increase as projected.

• Key man risk. Second BIGGEST risk. Everything rests on Dr. Rohit Sane and his vision and dream. The company over time will need to add more professionals to the business. Though, they do have some professionals like the CEO, CFO, Marketing head etc. in place.

• The failure to building Madhavbaug as a brand.

• Its B2C product venture fails to have the desired impact. Worse still it takes away time and limited company resources from its main mission of building more clinics and hospitals. It has happened in H1 FY24 where the management was busy in marketing its Madhvprash product and this impacted the sales, margins and profits.

• General management missteps and highly ambitious goals that fail to materialize beyond presentations and excel sheets.

In summary,

• PE ratio: 70 at CMP of 215. With ~20% growth on the exit EPS of FY23 (4.59) works out to an EPS of 5.50, thus resulting in a PE of 39 for FY24. One-year forward EPS of 6.6, results in a PE of 32.57. Is this cheap? Well not really, but for a company poised to grow for a decent period of 3-5 years with an expected expansion in margins, it is not overly expensive either. I think it is fairly valued
• PEG ratio: At a PE of 39 (FY24) and PE of 32.57 (FY25), there is a chance that the company will grow its profits at these speeds or higher over the next 3-5 years. Thus, it should have a PEG of 1 or under, again making me believe it is fairly valued
• Price to sales ratio: The company is available at P/S ratio of ~1.87 on FY24 exit sales (Mkt cap 224 crs /120 crs revenue) and ~1.55 on FY25 exit sales (Mkt cap 224 crs / 144 cr FY25 sales). The question I ask myself, will I buy a business under 2 times sales? At this juncture, I’m getting a fast growing business with – cash on books, land and buildings, tech and systems in place to grow and scale, a somewhat proven business model, trained staff and processes and a hardworking promoter/owner. The answer is, hell yes!
• Stock is down ~42% from its 52-week high, it is already beaten down and some of the early hype about the business seems to have faded away. Can it fall further? Sure, in case of market corrections and poor results, it may go down further, but to me the downside from here looks limited. For e.g. if it goes down another ~30% (under normal market conditions), I would suspect there is something wrong with the business/promoter. A company with a clean balance sheet like this shouldn’t get hammered further (at least in my experience).
• In the last fund raise in July 2023, a set of marquee investors were issued warrants at 261, currently it is trading below that. I ask myself, if they saw value at 261, why can’t I at this stage?

Thus, my general consensus is that the stock seems fairly valued at this juncture and should do well with as the business grows and scales

Sources:

1. All projections and details are based off numbers shared by management in their publicly available concall and interview
2. Numbers have been taken from Screener
3. Comparative PE ratios of companies in the similar business of hospitals, clinics and diagnostics

Disc: Invested as a tactical 2-4 year bet. May hold longer depending on how management executes its plans. Position size is 2.3% of my entire pf.